Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor

Area of Science:

• Oncology
• Pharmacology

Background:

• Cabozantinib is an oral small-molecule multitargeted tyrosine kinase inhibitor (TKI).
• It targets multiple receptors, potentially offering advantages over single-target TKIs.
• Approved for advanced renal cell carcinoma and metastatic medullary thyroid cancer, its investigation spans numerous other cancers.

Purpose of the Study:

• To detail the rationale, clinical trial data, and recommendations for cabozantinib use.
• To review common adverse events and discuss management strategies.
• To provide implications for practitioners regarding the expanding use of cabozantinib.

Main Methods:

• Review of clinical trial data for cabozantinib in various cancers.
• Analysis of approved indications and ongoing investigations.
• Compilation of information on adverse event profiles and management.

Main Results:

• Cabozantinib is approved for advanced renal cell carcinoma and metastatic medullary thyroid cancer.
• Clinical data supports its investigation in prostate, hepatocellular, and lung cancers.
• Common adverse events are identified, with management strategies outlined.

Conclusions:

• Cabozantinib's multitargeted approach offers potential benefits in oncology.
• Its use is expanding beyond initial approvals to other cancer types.
• Understanding its efficacy and safety profile is crucial for practitioners.